Le Lézard
Classified in: Health, Business
Subjects: TNM, RCN

Essex Capital Arranges $95 Million Acquisition Recapitalization


TAMPA, Fla., Nov. 15, 2018 /PRNewswire/ -- Essex Capital Group, Inc. ("Essex"), announced today that the firm recently arranged a $95,000,000 acquisition financing and recapitalization for CAN Community Health, Inc. ("CAN" or the "Company"), a private, not-for-profit organization dedicated to the treatment, care and continual wellness of people living with HIV, hepatitis C, STDs and other diseases. The Company has been serving the needs of the HIV community in Florida and the Southeast US since 1991.  CAN currently operates 34 medical clinics, offering medical, dental, psychological and lifestyle counseling to all patients, regardless of their financial situation, insurance status, or ability to pay.

As a part of this transaction, Essex structured and negotiated two separate specialty pharmacy company acquisitions on behalf of CAN, subsequently arranging a comprehensive acquisition term debt financing solution.

The financing structure also provided a $30 million merchant card program to fund the tremendous organic growth currently being experienced by the Company.

Richard E. Carlisle, CAN CEO commented: "We recognized an opportunity to vertically integrate our business through two pharmacy acquisitions. In hiring an investment banking firm to negotiate, structure and finance these transactions, we interviewed several firms. After a detailed review of available options, we chose to hire Essex Capital Group to lead the process."

"Working closely with Rob and Bob over the last 6 months was a pleasure. They delivered on what they said they would do, and they exceeded my expectations in the level of professionalism, deal structuring creativity and tenacity displayed in getting a complicated transaction completed. We now consider Essex a vital business partner as we move forward with other growth opportunities."

Essex Capital acted as the Company's exclusive financial advisor in this transaction.

Robert Swain
President
Essex Capital Group, Inc.
8138373500
[email protected]

This release was issued through WebWire®. For more information, visit http://www.webwire.com.

SOURCE Essex Capital Group, Inc.


These press releases may also interest you

at 22:18
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

at 22:03
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

at 22:00
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

at 21:45
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...

at 21:30
The "Whole Genome and Exome Sequencing Markets by Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Will all...

at 20:50
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D investment was RMB372 million, the cash and cash equivalent at the end of 2023 was...



News published on and distributed by: